tbuckley/cabot-search huggingface dataset:
The ideomotor recycling theory for language
Authors: Arnaud Badets
Journal: Behavioral and Brain Sciences (2016)

Abstract For language acquisition and processing, the ideomotor theory predicts that the comprehension and the production of language are functionally based on their expected perceptual effects (i.e., linguistic events). This anticipative mechanism is central for action–perception behaviors in human and nonhuman animals, but a recent ideomotor recycling theory has emphasized a language account throughout an evolutionary perspective.
Basal ganglia phosphorous metabolism in chronic schizophrenia
Authors: R F Deicken, G Calabrese, E L Merrin, G Fein, M W Weiner
Journal: American Journal of Psychiatry (1995)

The authors examined whether there are abnormalities in high-energy phosphorous metabolism in the basal ganglia of schizophrenic patients.In vivo 31P magnetic resonance spectroscopic imaging was performed on 18 chronic schizophrenic patients and 16 healthy comparison subjects. The percentages of total phosphorous signal for phosphomonoesters, inorganic phosphate, phosphodiesters, phosphocreatine, and beta-ATP were calculated.The mean percentages of beta-ATP signal in the right and left basal ganglia were significantly lower for the schizophrenic patients than for the comparison group. No other group differences in phosphorous metabolites and no lateral asymmetries in the schizophrenic group were noted.This preliminary study provides support for abnormal high-energy phosphorous metabolism in the basal ganglia of schizophrenic patients.
Skin microbiota is the main reservoir of Roseomonas mucosa , an emerging opportunistic pathogen so far assumed to be environmental
Authors: S. Romano-Bertrand, A. Bourdier, F. Aujoulat, A.-L. Michon, A. Masnou, S. Parer, H. Marchandin, E. Jumas-Bilak
Journal: Clinical Microbiology and Infection (2016)
In between
Authors: T S Stein
Journal: Annals of Internal Medicine (1998)

On Being a Patient15 December 1998In betweenTerry S. Stein, MDTerry S. Stein, MDOakland, CA 94612Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-129-12-199812150-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail She sat hunched, ghostlike, eyes glazed and spirit absent. I stared, disbelieving, feeling hollow inside, as if grieving a death but not quite. I took her fragile hand and instructed her, as I would a child, to get up and move her feet forward, one at a time. The physician in me needed to take charge; the daughter in me felt bereft.My mind flew to earlier images, from the shadow next to me to the memories of the fierceness that had been my mother. Although she used to occupy endless space-or at least the 400 miles from her house ... Author, Article, and Disclosure InformationAuthors: Terry S. Stein, MDAffiliations: Oakland, CA 94612Corresponding Author: Terry S. Stein, MD, Department of Physician Education and Development, 1800 Harrison, 21st Floor, Oakland, CA 94612; e-mail, [email protected] PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 December 1998Volume 129, Issue 12Page: 1074KeywordsChildrenCognitionEmotionsFoodForecastingFrailtyHand strengthMemoryScars ePublished: 15 August 2000 Issue Published: 15 December 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
THU0185 Safety, Pharmacokinetics and Proof-of-mechanism of an Oral Bruton's Tyrosine Kinase Inhibitor HM71224 in Healthy Adult Volunteers
Authors: J. Lee, J. Son, H.J. Sin, J. Woo, S. Hadi, K.H. Suh, Y.-M. Lee, S. Jang, J.-A. Jung
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> HM71224 is an orally available, irreversible and highly selective small molecule inhibiting Bruton9s Tyrosine Kinase (BTK) which plays key roles in B-cell receptor (BCR) and Fc receptor (FcR) signaling cascades and B cell development and activation. HM71224 showed strong efficacy in mice and rat collagen induced arthritis models, dose-proportional pharmacokinetic (PK) profile and acceptable tolerability in healthy male volunteers. Therefore, HM71224 may provide a new therapeutic option for active rheumatoid arthritis (RA). We hereby report updated data from the first in man clinical study with HM71224 (NCT01765478). <h3>Objectives</h3> To evaluate safety, tolerability, PK and pharmacodynamics (PD) of HM71224 following once daily or twice daily multiple ascending dose (MAD) in healthy volunteers. <h3>Methods</h3> MAD part was performed in a randomized, double-blind, placebo-controlled design in which subjects were administered HM 71224 once daily (10 mg ∼120mg) or twice daily (5mg ∼ 60mg) for 14 days. Adverse events (AEs) were monitored throughout the study. Blood samples were collected to measure HM71224/metabolites concentration and explore PD effect such as BTK occupancy. <h3>Results</h3> HM71224 showed good safety profile up to once daily MAD of 80 mg HM71224. No drug-related serious AEs were reported in twice daily MAD dosing. Following multiple ascending administration of HM71224, exposure in plasma (C<sub>max</sub> and AUC<sub>0-t</sub>) increased approximately dose-proportionally. BTK occupancy was increased with blood concentration of parent HM71224 and above 90 percent of BTK occupancy was achieved at a trough level with 20 mg twice daily MAD. <h3>Conclusions</h3> HM71224 is being developed as a BTK inhibitor for RA treatment. HM71224 demonstrated well-tolerated safety profile in HVs and desirable PK and PD properties supporting sustained target inhibition. Phase 2 study will be initiated in active RA patients soon. <h3>References</h3> Bioessays. 2001 May; 23(5):436-46. Nat Rev Immunol. 2002 Dec; 2(12):945-56. Nat Rev Drug Discov. 2003 Jun; 2(6):473-88. Immunol Rev. 2007 Aug; 218:45-64. Immunol Rev. 2009 Mar; 228(1):58-73. Nat Rev Rheumatol. 2009 Jun; 5(6):317-24. Int Rev Immunol. 2012 Apr; 31(2):119-32. Clin Immunol. 2013 Jul; 148(1):66-78. <h3>Disclosure of Interest</h3> J. Lee Employee of: Hanmi Pharmaceutical Co., Ltd., J. Son Employee of: Hanmi Pharmaceutical Co., Ltd., H. J. Sin Employee of: Hanmi Pharmaceutical Co., Ltd., J. Woo Employee of: Hanmi Pharmaceutical Co., Ltd., S. Hadi: None declared, K. H. Suh Employee of: Hanmi Pharmaceutical Co., Ltd., Y.-M. Lee Employee of: Hanmi Pharmaceutical Co., Ltd., S. Jang Employee of: Hanmi Pharmaceutical Co., Ltd., J.-A. Jung Employee of: Hanmi Pharmaceutical Co., Ltd.
Low frontal glucose utilization in chronic schizophrenia: a replication study
Authors: A Wolkin, B Angrist, A Wolf, J D Brodie, B Wolkin, J Jaeger, R Cancro, J Rotrosen
Journal: American Journal of Psychiatry (1988)

Frontal/posterior ratios of cerebral glucose metabolism as determined by positron emission tomography were significantly lower in 13 chronic schizophrenic patients than in eight normal control subjects, as were absolute metabolic rates in both the frontal and posterior regions. The differences were not accounted for by cerebral atrophy.
AB0432 Dose Escalation and Switching Patterns of Anti-TNF Drugs in Rheumatoid Arthritis: A Retrospective Chart – Review Study in Turkey: Table 1.
Authors: U. Kalyoncu, S.Z. Aydin, E. Dalkilic, T. Kaşifoglu, B. Kisacik, Ö. N. Pamuk, S. Yilmaz, A. Yazıcı, V. Yazısız, S.S. Koca, M.F. Öksüz
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> There is not enough data on the dosing patterns and switching rates of the most frequently used TNFis infliximab, adalimumab and etanercept in Turkey. <h3>Objectives</h3> The aim of this retrospective chart review is to compare the proportion of rheumatoid arthritis (RA) subjects requiring treatment modification between the TNFis (etanercept, infliximab and adalimumab). <h3>Methods</h3> Inclusion criterias; a) Consecutive patients diagnosed with RA who were newly started on TNFis as the first biologic treatment. b) Have received continuous treatment with the index TNFi (the date of initial prescription of a TNFi is considered index date and the TNFi itself is the index TNFi) for at least 3 months following the index date and with a biologic (either the index drug or other biologic to which he/she was switched due to inefficacy) for at least 18 months. DMARDs and corticosteroids doses, dosing regimens and reasons for dose changes collected for 18 months following the index date. The primary end point is the proportion of patients with treatment modification which is defined as either one of the following: The first occurrence of any upward adjustment in dose or dosing frequency of each TNFi from the label/indicated dose and unit of time (etanercept 25 milligram [mg] biweekly or 50 mg once weekly, adalimumab 40 mg once every other week or infliximab 3mg/kilogram [kg] every 8 weeks after the 3rd infusion) within the 12 month period following index date. The first occurrence of any switch to another biologic agent due to inefficacy or loss of efficacy <h3>Results</h3> Overall 400 patients (79.3% female) were enrolled to this study. TNFi drugs were etanercept (240 patients), adalimumab (80 patients) and infliximab (80 patients) respectively. Mean age was 53±12 years old, mean disease duration was 11.3±7.5 years. Anti-CCP antibody was positive at 115/201 (57.2%), and rheumatoid factor was positive at 178/311 (57.2%) of patients. Baseline DAS-28 score was 5.75±0.79, baseline ESR and CRP were 45±26 mm/hour and 3.4±2.8 mg/dl, respectively. The distribution of modifications such as change of TNFi duration or dosage (modification 1), change of TNFi due to inefficacy or lost of efficacy (modification 2), increase of DMARDs or steroid dosage (modification 3) and add of DMARDs or steroid (modification 4) were shown at table 1. <h3>Conclusions</h3> Dose escalation was prominent at infliximab than other anti-TNF drugs. Patients with infliximab also had more frequent switch of TNFi due to inefficacy or loss of efficacy. However, increase or add of DMARD or steroid were similar at whole anti-TNF drugs. <h3>Acknowledgements</h3> This study was supported by Phizer, Inc. <h3>Disclosure of Interest</h3> None declared
THU0148 Structure of Co-morbid Diseases in Patients with Rheumatoid Arthritis in Saratov Region of Russia
Authors: I. Afanaciev, N. Nikitina, A. Rebrov
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Patients with rheumatoid arthritis (RA) usually have high rate of comorbidities. The co-morbid diseases may greatly decrease the quality of life. Pharmacological interaction between DMARD9s and medicines used to comorbidity9s treatment also may potentiate DMARD9s unacceptable effects. <h3>Objectives</h3> The aim of the current study was to analyze a structure of co-morbid diseases in patients with RA in Saratov region of Russia. <h3>Methods</h3> The study involved 328 patients with RA diagnosed with ACR (1987) and EULAR/ACR 2010 criteria observed in 2011-2013 years. The group included 17,4% men and 82,6% women; mean age was 54,6±12,6 years. Anamnesis of RA mean longevity was 10,4±9,8 years. All patients receive DMARDs by 3 month or longer. The clinical examination, questioning and data from the patient9s card were evaluated. <h3>Results</h3> Comorbidities was occurred in 86,6% of patients. 57,9% persons have 2 or more comorbid disorders. The most common co-morbid conditions were cardiovascular diseases (88,6%) includes arterial hypertension (57,7%) and ischemic heart disease (30,9%). Gastrointestinal disorders occurred in 80,3% patients: chronic inflammatory diseases of stomach and duodenum - 39,8%, chronic cholecystitis –27,1%, pancreatitis –16,5%, 5,6% patients have HCV-hepatitis. 50,7% patients have osteoarthritis (OA). 71,5% patients OA firstly occurred after then RA has been diagnosed. Diseases of endocrinous system was diagnosed in 24,6% patients: 19,7% persons have autoimmune thyreoiditis, diabetes mellitus occurred in 4,9% patients. 11,9% patients have varicose of lower extremities. Chronic pyelonephritis occurred in 19,7% persons. 9,5% patients have respiratory disorders: chronic obstructive pulmonary disease occurred in 2,1%, bronchial asthma – in 7,4% patients. <h3>Conclusions</h3> Comorbidities are high-frequent conditions in patients with rheumatoid arthritis. The most common comorbid disorders are arterial hypertension and osteoarthritis. Acute inflammatory gastrointestinal and uretero-vesical diseases may become barriers to the DMARD9s using. Activity of co-morbid disorders makes treating RA to target difficultly. <h3>Disclosure of Interest</h3> None declared
Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials
Authors: Lola Rahib, Julie M. Fleshman, Lynn M. Matrisian, Jordan D. Berlin
Journal: JAMA Oncology (2016)

Progress in the treatment of pancreatic adenocarcinoma has been minimal; it remains the only major cancer type with a 5-year survival rate of less than 10%.To explore why a large proportion of advanced pancreatic cancer clinical trials executed over the past 25 years have had negative results and to identify benchmarks that could have predicted success.Phase 3 studies of patients with advanced pancreatic cancer were identified by searching clinicaltrials.gov and the scientific literature.Thirty-two phase 3 studies in 13 675 chemotherapy-naive patients resulted in 3 agents or combinations being considered clinically meaningful. Nineteen agents or combinations (70%) were tested in phase 2 trials preceding the phase 3 trial. In cases with paired phase 2 and 3 results, meeting the primary end point of the phase 2 trial predicted the outcome of the phase 3 trial 76% of the time but proceeded despite phase 2 negative results in 10 cases. We applied criteria for a clinically meaningful result identified by the American Society of Clinical Oncology (ASCO) Cancer Research Committee to these historical cases. Overall, progression-free and 1-year survival of experimental arms was compared with time period-controlled median values of control arms to normalize for the observed increase in response to gemcitabine over time.Applying the benchmark of a 50% improvement in overall survival as the primary end point to phase 2 data, or secondary end points of a 90% increase in 1-year survival or an 80% to 100% increase in progression-free survival, showed the greatest ability to predict a clinically meaningful phase 3 trial. Had these criteria been applied to these trials over the past 25 years, more than 11 571 patients enrolled in phase 3 trials that did not meet the primary end point could theoretically have been diverted to earlier-stage trials in an attempt to more rapidly advance the field.
Outbreak of verocytotoxin-producing E. coli O145 and O26 infections associated with the consumption of ice cream produced at a farm, Belgium, 2007
Authors: K De Schrijver, G Buvens, B Possé, D Van den Branden, O Oosterlynck, L De Zutter, K Eilers, D Piérard, K Dierick, R Van Damme-Lombaerts, C Lauwers, R Jacobs
Journal: Eurosurveillance (2008)

In October 2007, an outbreak of verocytotoxin-producing Escherichia coli (VTEC) O145 and E. coli O26 occurred among consumers of ice cream produced and sold in September 2007 at a farm in the province of Antwerp (Belgium). The ice cream was consumed at two birthday parties and also eaten at the farm. Five children, aged between two and 11 years, developed haemolytic uraemic syndrome (HUS), and seven other co-exposed persons contracted severe diarrhoea. In three of the five HUS cases VTEC O145 infections were laboratory confirmed, one in association with VTEC O26. Identical isolates of E. coli O145 and O26 were detected with PCR and PFGE in faecal samples of patients and in ice cream leftovers from one of the birthday parties, in faecal samples taken from calves, and in samples of soiled straw from the farm at which the ice cream was produced. Ice cream was made from pasteurised milk and most likely contaminated by one of food handlers.
Stage 4S neuroblastoma: what makes it special?
Authors: K K Matthay
Journal: Journal of Clinical Oncology (1998)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1998.16.6.2003 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9626196 Stage 4S neuroblastoma: what makes it special? K K MatthayxK K MatthaySearch for articles by this author https://doi.org/10.1200/JCO.1998.16.6.2003 First Page PDF © 1998 by American Society of Clinical Oncology
THU0361 Increased Body Mass Index and Biologics Drug Survival in Patients with Inflammatory Rheumatic Diseases
Authors: O. Elkayam, M. Lidar, T. Reitblat, A. Balbir-Gurman, R. Almog
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Recent studies have suggested that obesity may reduce the response rate to TNFα blockers (1,2). <h3>Objectives</h3> The objective of this study was to determine whether body mass index (BMI) affects drug survival of Tumor Necrotic Factor (TNF)-α blockers in patients suffering from rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS). <h3>Methods</h3> The data were extracted from the prospective Israeli registry for use of biological agents in patients treated with TNF-α blockers for RA, PsA and AS. Patients were divided according to the baseline BMI as normal BMI (BMI &lt;25), overweight (BMI 25-30, 30-35) and obese (BMI&gt;35). The drug survival was analyzed using the Kaplan-Meier curves. The influence of different covariates on drug survival was analyzed by Cox regression. <h3>Results</h3> 574 patients (344 patients with RA, 131 with PSA and 99 with AS) from four Israeli Academic center for rheumatic diseases received 1218 treatment series (etanercept-305, adalimumab-244, infliximab -257); 635 of them were discontinued (391 (62%) because of loss of efficacy. The distribution of BMI was higher but not statistically significant in PsA (median 27.4, IQR 24,3-30.8) in comparison with RA (26.2,23.4-30.5) and AS (26.8,24.1-30.1). Significant overall correlation was found between BMI and biologic treatment effectiveness survival (log-rank p=0.022) for all biologics (non-anti TNF α agents) and (log-rank p=0.011) for anti TNF-α agent particularly. Looking at each of the 3 anti-TNF- α agent separately the association was significant for etanercept drug survival (log-rank p=0.028) but not for Infliximab or adalimumab. Etanercept median survival was 1343, 961, 700, and 580 days for BMI &lt;25,25-30,30-35, and &gt;35 respectively. <h3>Conclusions</h3> Increased BMI significantly decreases the drug survival of etanercept in patients with AS, RA, and PsA. Our study results provide basis to suggest that in patients with increased BMI, etanercept should not be recommended as the 1st TNF α blocker <h3>References</h3> Iannone F, Fanizzi R, Notarnicola A, Scioscia C, Anelli M, Lapadula G. Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients. Joint Bone Spine. 2015 Jan 22 Gremese E, Bernardi S, Bonazza S, Nowik M, Peluso G, Massara A et al. Body weight, gender and response to TNF-α blockers in axial spondyloarthritis. Rheumatology (Oxford). 2014 May;53(5):875-81 <h3>Disclosure of Interest</h3> None declared
Case 44-1970
Authors: Richard C. Cabot, Benjamin Castleman, Betty U. McNeely, Robert H. Schapiro, Stanley J. Robboy, Benjamin Castleman
Journal: New England Journal of Medicine (1970)

Presentation of CaseA 15-year-old girl was admitted to the hospital because of hepatitis.Ten months previously her ears had been pierced by a physician. At about that time a classmate contracted hepatitis. One month later jaundice developed insidiously, with the passage of dark urine and light stools, although she felt well except for fatigue. One week of bed rest was followed by transient improvement. Nausea, fever and cold sweats developed abruptly, and she was admitted to another hospital, where she remained for 29 days. On admission the bilirubin was 20.8 mg, total, and 14 mg, direct, per 100 ml; . . .
Case 3-1982
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, Betty U. McNeely, Nancy L. Sprince, Eugene J. Mark
Journal: New England Journal of Medicine (1982)

Presentation of CaseA 73-year-old woman was admitted to the hospital because of dyspnea.There was a 25-year history of mild recurrent poly-arthritis. Nineteen years before admission a test for rheumatoid factor was positive in a titer of 1:1920. Repeated x-ray films of the chest taken over many years were normal. Seven years before entry the patient came to the clinic with the complaint of bronchitis. On examination a few persistent fine rales were audible at the bases of both lungs; the heart was normal. An x-ray film of the chest revealed diffuse areas of minimal fibrosis at the bases . . .
Response to Letter Regarding Article, “Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction”
Authors: Rajalakshmi Santhanakrishnan, Na Wang, Martin G. Larson, Jared W. Magnani, David D. McManus, Steven A. Lubitz, Patrick T. Ellinor, Susan Cheng, Ramachandran S. Vasan, Douglas S. Lee, Thomas J. Wang, Daniel Levy, Emelia J. Benjamin, Jennifer E. Ho
Journal: Circulation (2016)
SAT0186 Tocilizumab Improved of the Quality of the Life Patients with Severe/Moderate RA (Lornet Study): Table 1.
Authors: E. Panasyuk, E. Nasonov
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Health-related quality of life (HR-QoL) in patients with rheumatoid arthritis (RA) is important part of patients status, and become main outcome measure in clinical practice and trials. Tocilizumab (TCZ), anti-interleukin-6 receptor monoclonal antibody was used in treatment of active rheumatoid arthritis (RA). <h3>Objectives</h3> To evaluate efficacy of TCZ on HR-QoL as measured by 36-Item Short Form Health Survey (SF-36) subscales, Health Assessment Questionnaire Disability Index (HAQ-DI) and EuroQoL-5D (EQ-5D) in LORNET study and to show the influence of TCZ on the results of treatment. <h3>Methods</h3> LORNET (Local Open-label multicentre study quality of life patients with moderate and severe RA having iNadEquaTely responded to DMARDs) is study in patients who initiated treatment with TCZ. Patient had to be naïve to biologics and have moderate to severe active RA (1987 ACR criteria) to be included in the 6-month trial. A total 201 adult patients with active RA (DAS&gt;3,2) who remained on stable doses of DMARDs and received TCZ 8 mg/kg every 4 weeks for 24 weeks (total 6 infusions) were enrolled in the study. Patient completed the SF-36 and EQ-5D questionnaire at baseline and week 24. HAQ-DI evaluation was performed on every 4 weeks. <h3>Results</h3> Baseline characteristics of 201 patients included: mean (SD) age 49 (12), disease duration 7,5 (6,5) years, HAQ-DI 1,93±0,6. Average disease activity score (DAS) 28 of all 201 patients significantly decreased from 6,75±0,85 (baseline) to 2,6±1,16 (week 24). DAS28 remission (DAS28&lt;2,6) rate at week 24 being achieved by 51,3%, SDAI remission – 21,4%, CDAI remission – 22,0%. Significant mean improvement at week 24 from baseline weas seen in SF-36 subscales and EQ-5D outcomes. EQ-5D improvement was seen at week 24, delta EQ-5D was performed 0,41±0,33 (minimal clinical difference is - 0,01). Improvements in physical functioning measured by HAQ-DI and delta HAQ-DI -0,44 (minimal clinical difference is -0,22) were observed early at week 4, and were sustained for treatments duration. At week 24 delta HAQ-DI amount to 1,11±0.66. <h3>Conclusions</h3> Tocilizumab in combination with DMARDs showed significant and clinically meaningful improvements in social and leisure activities in patient with moderate to severe RA. Rapid and sustained improvement was noted in quality of life. <h3>Disclosure of Interest</h3> None declared